{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T21:34:15Z","timestamp":1783200855463,"version":"3.54.6"},"reference-count":37,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.ad.2019.01.001","type":"journal-article","created":{"date-parts":[[2019,3,2]],"date-time":"2019-03-02T16:30:09Z","timestamp":1551544209000},"page":"533-545","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Documento de consenso espa\u00f1ol para el algoritmo de tratamiento de la ros\u00e1cea"],"prefix":"10.1016","volume":"110","author":[{"given":"M.","family":"Salleras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Alegre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Alonso-Usero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Boixeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Dom\u00ednguez-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Fern\u00e1ndez-Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Garc\u00eda-Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Llamas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Nadal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"del Pozo-Losada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Querol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Salg\u00fcero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schaller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Soto de Del\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2019.01.001_bib0190","doi-asserted-by":"crossref","unstructured":"Intervenciones para la ros\u00e1cea (Revisi\u00f3n Cochrane traducida). Cochrane Database Syst Rev. 2015;4(CD003262). Doi: 10.1002\/14651858.CD003262.","DOI":"10.1002\/14651858.CD003262"},{"key":"10.1016\/j.ad.2019.01.001_bib0195","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.piel.2015.05.010","article-title":"Ros\u00e1cea. Impacto psicosocial","volume":"31","author":"Garc\u00eda-Bust\u00edndy","year":"2016","journal-title":"Piel (Barc)"},{"key":"10.1016\/j.ad.2019.01.001_bib0200","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000136656","article-title":"Prevalence of skin diseases in a cohort of 48,665 employees in Germany","volume":"217","author":"Schaefer","year":"2008","journal-title":"Dermatology."},{"key":"10.1016\/j.ad.2019.01.001_bib0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.piel.2015.02.010","article-title":"Ros\u00e1cea: actualizaci\u00f3n","author":"Barona","year":"2015","journal-title":"Piel (Barc)."},{"key":"10.1016\/j.ad.2019.01.001_bib0210","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2340\/00015555-0856","article-title":"Prevalence of rosacea in an Estonian working population using a standard classification","volume":"90","author":"Abram","year":"2010","journal-title":"Acta Derm Venereol."},{"issue":"Suppl 3","key":"10.1016\/j.ad.2019.01.001_bib0215","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1016\/S0151-9638(11)70087-4","article-title":"Epidemiology of rosacea: Updated data","volume":"138","author":"Chosidow","year":"2011","journal-title":"Ann Dermatol Venereol."},{"key":"10.1016\/j.ad.2019.01.001_bib0220","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJMcp042829","article-title":"Clinical practice. Rosacea","volume":"352","author":"Powell","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2019.01.001_bib0225","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/jidsymp.2011.7","article-title":"Clinical, cellular, and molecular aspects in the pathophysiology of rosacea","volume":"15","author":"Steinhoff","year":"2011","journal-title":"J Investig Dermatol Symp Proc."},{"key":"10.1016\/j.ad.2019.01.001_bib0230","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1468-3083.2009.03472.x","article-title":"Risk factors associated with rosacea","volume":"24","author":"Abram","year":"2010","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.ad.2019.01.001_bib0235","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.semerg.2010.08.004","article-title":"Ros\u00e1cea: revisi\u00f3n y nuevas alternativas terap\u00e9uticas","volume":"37","author":"Gil-D\u00edaz","year":"2011","journal-title":"Semergen."},{"key":"10.1016\/j.ad.2019.01.001_bib0240","first-page":"650","article-title":"Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: Results of two randomized, double-blind, and vehicle-controlled pivotal studies","volume":"12","author":"Fowler","year":"2013","journal-title":"J Drugs Dermatol."},{"key":"10.1016\/j.ad.2019.01.001_bib0245","first-page":"316","article-title":"Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: Results of two randomized, double-blind, vehicle-controlled pivotal studies","volume":"13","author":"Stein","year":"2014","journal-title":"J Drugs Dermatol."},{"key":"10.1016\/j.ad.2019.01.001_bib0250","first-page":"234","article-title":"Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 1: a status report on the disease state, general measures, and adjunctive skin care","volume":"92","author":"Del Rosso","year":"2013","journal-title":"Cutis."},{"key":"10.1016\/j.ad.2019.01.001_bib0255","first-page":"277","article-title":"Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 2: A status report on topical agents","volume":"92","author":"Del Rosso","year":"2013","journal-title":"Cutis."},{"key":"10.1016\/j.ad.2019.01.001_bib0260","first-page":"18","article-title":"Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 3: A status report on systemic therapies","volume":"93","author":"Del Rosso","year":"2014","journal-title":"Cutis."},{"key":"10.1016\/j.ad.2019.01.001_bib0265","first-page":"71","article-title":"Consensus recommendations from the American acne & rosacea society on the management of rosacea, part 4: A status report on physical modalities and devices","volume":"93","author":"Tanghetti","year":"2014","journal-title":"Cutis."},{"key":"10.1016\/j.ad.2019.01.001_bib0270","first-page":"134","article-title":"Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 5: A guide on the management of rosacea","volume":"93","author":"Del Rosso","year":"2014","journal-title":"Cutis."},{"key":"10.1016\/j.ad.2019.01.001_bib0275","first-page":"CD003262","article-title":"Interventions for rosacea","author":"Van Zuuren","year":"2015","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.ad.2019.01.001_bib0280","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jid.2016.01.025","article-title":"A randomized controlled trial of oral low dose isotretinoin for difficult to treat papulopustular rosacea","volume":"136","author":"Shidan","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ad.2019.01.001_bib0285","unstructured":"Programa en habilidades de lectura cr\u00edtica espa\u00f1ol. Espa\u00f1a [Internet].CASPE [consultado 12 mayo 2016]. Disponible en: http:\/\/.redcaspe.org."},{"key":"10.1016\/j.ad.2019.01.001_bib0290","unstructured":"GRADE working group [Internet] [consultado 12 mayo 2016]. Disponible en: http:\/\/www.gradeworkinggroup.org\/_es\/faq\/index.htm"},{"key":"10.1016\/j.ad.2019.01.001_bib0295","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ijar.2006.06.024","article-title":"Consensus and dissention: A measure of ordinal dispersion Internat","volume":"45","author":"Tastle","year":"2007","journal-title":"J Approx Reason."},{"key":"10.1016\/j.ad.2019.01.001_bib0300","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1067\/mjd.2002.120625","article-title":"Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea","volume":"46","author":"Wilkin","year":"2002","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2019.01.001_bib0305","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bjd.12385","article-title":"An observational cross-sectional survey of rosacea: Clinical associations and progression between subtypes","volume":"169","author":"Tan","year":"2013","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2019.01.001_bib0310","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2340\/00015555-1976","article-title":"Health-related quality of life in patients with cutaneous rosacea: A systematic review","volume":"95","author":"Van der Linden","year":"2015","journal-title":"Acta Derm Venereol."},{"key":"10.1016\/j.ad.2019.01.001_bib0315","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1365-2133.2011.10716.x","article-title":"Once-daily topical brimonidine tartrate gel 0\u00b75% is a novel treatment for moderate to severe facial erythema of rosacea: Results of two multicentre, randomized and vehicle-controlled studies","volume":"166","author":"Fowler","year":"2012","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2019.01.001_bib0320","unstructured":"National Health Service (NHS). Rosacea-treatment. 2014 [consultado 17 julio 2016]. Disponible en: http:\/\/www.nhs.uk\/Conditions\/Rosacea\/Pages\/Treatment.aspx"},{"key":"10.1016\/j.ad.2019.01.001_bib0325","first-page":"38","volume":"34","author":"Culp","year":"2009","journal-title":"Rosacea: A review. P T."},{"key":"10.1016\/j.ad.2019.01.001_bib0330","unstructured":"Ficha t\u00e9cnica Brimonidina. Mirvaso((Laboratorios Galderma S.A.). Disponible en: http:\/\/www.ema.europa.eu\/docs\/es_ES\/document_library\/EPAR_-_Product_Information\/human\/002642\/WC500163121.pdf \u00daltimo acceso: octubre 2016."},{"key":"10.1016\/j.ad.2019.01.001_bib0335","first-page":"159","article-title":"Update on the management of rosacea","volume":"8","author":"Weinkle","year":"2015","journal-title":"Clin Cosmet Investig Dermatol."},{"key":"10.1016\/j.ad.2019.01.001_bib0340","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2340\/00015555-2335","article-title":"Facial erythema of rosacea. Aetiology different pathophysiologies and treatment options","volume":"96","author":"Steinhoff","year":"2016","journal-title":"Acta Derm Venereol."},{"key":"10.1016\/j.ad.2019.01.001_bib0345","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/bjd.13408","article-title":"Superiority of ivermectin 1% cream over metronidazole 0,75% cream in treating inflammatory lesions of rosacea: A randomized, investigator-blinded trial","volume":"172","author":"Taieb","year":"2015","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2019.01.001_bib0350","first-page":"1380","article-title":"Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials","volume":"13","author":"Stein Gold","year":"2014","journal-title":"J Drugs Dermatol."},{"key":"10.1016\/j.ad.2019.01.001_bib0355","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jaad.2006.11.021","article-title":"Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline USP capsules) administered once daily for treatment of rosacea","volume":"56","author":"Del Rosso","year":"2007","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2019.01.001_bib0360","first-page":"573","article-title":"Comparison of anti-inflammatory dose doxycycline versus doxycycline 100mg in the treatment of rosacea","volume":"7","author":"Del Rosso","year":"2008","journal-title":"J Drugs Dermatol."},{"key":"10.1016\/j.ad.2019.01.001_bib0365","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3810\/pgm.2009.09.2066","article-title":"Updates on the pathophysiology and management of acne rosacea","volume":"121","author":"Elsaie","year":"2009","journal-title":"Postgrad Med."},{"key":"10.1016\/j.ad.2019.01.001_bib0370","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/j.1468-3083.2009.03167.x","article-title":"Current topical and systemic approaches to treatment of rosacea","volume":"23","author":"Korting","year":"2009","journal-title":"J Eur Acad Dermatol Venereol."}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731019300080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731019300080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:08:27Z","timestamp":1757552907000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731019300080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0001731019300080"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2019.01.001","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Documento de consenso espa\u00f1ol para el algoritmo de tratamiento de la ros\u00e1cea","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2019.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 AEDV. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}